4 Healthcare Stock Stories for the Weekend
Pfizer (NYSE:PFE): Closing price $26.54
On Friday, Pfizer said that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion concerning the conditional marketing authorization of bosutinib in the European Union for the treatment of adult patients suffering from chronic phase, accelerated phase, and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor, and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. The CHMP’s positive opinion will be evaluated by the European Commission, which has the authority to approve medicines for the EU. Pfizer expects a decision from the Commission in the coming months.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>